Denali Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at ...
Denali Gains 26.6% in a Year: How Should You Play the Stock?
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
Nasdaq5d
Denali Gains 26.6% in a Year: How Should You Play the Stock?
Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry’s decline of 14.3%. The stock has also ...
Investing2d
Denali Therapeutics Inc (DNLI)
Jefferies (NYSE:JEF) analyst Michael Yee maintained a Buy rating on Denali Therapeutics (NASDAQ:DNLI) on Sunday, setting a price target of $95, which is approximately 48.67%... Evercore ISI ...
Nasdaq5d
DNLI Makes Bullish Cross Above Critical Moving Average
In trading on Tuesday, shares of Denali Therapeutics Inc (Symbol: DNLI) crossed above their 200 day moving average of $23.11, changing hands as high as $23.33 per share. Denali Therapeutics Inc ...
The Globe and Mail3d
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...
BioSpace3d
FDA Tacks Boxed Warning on Teva’s Copaxone, Other MS Drugs
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...